Analytics Made Easy - StatCounter

The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission.

Posted by Clinical on Dec 5th 2017

Parkinson’s disease (PD) is a neurodegenerative disorder for which available treatments provide symptom relief but do not stop disease progression. Mitochondria, and in particular mitochondrial dynamics, have been postulated as plausible pharmacological targets. Mitochondria-targeted antioxidants have been developed to prevent mitochondrial oxidative damage, and to alter the involvement of reactive oxygen species (ROS) in signaling pathways. (more)